Prague Med. Rep. 2026, 127, 145-150
https://doi.org/10.14712/23362936.2026.21
Resmetirom: A New FDA-approved Drug as a Targeted Therapeutic Strategy in Metabolic Dysfunction Associated Steatohepatitis: Translational Evidence from Current Clinical Trials
Ghulam Hassam-u-din Tarrar1, Syed Shafaat Hussain2, Muhammad Raza Sarfraz1,3
, Malka A. Hassan4, Tushar Kanti Bhadra5
, Malka A. Hassan4, Tushar Kanti Bhadra5
1Bahria University Health Science, Karachi, Pakistan
2Aga Khan University Hospitals, Karachi, Pakistan
3Allied Hospital, Faisalabad Medical University, Faisalabad, Pakistan
4Faculty of Medicine, Alexandria University, Alexandria, Egypt
5Dhaka Medical College, Dhaka, Bangladesh
Received May 21, 2025
Accepted September 8, 2026
Individual author index pages
- Ghulam Hassam-u-din Tarrar
- Syed Shafaat Hussain
- Muhammad Raza Sarfraz
- Malka A. Hassan
- Tushar Kanti Bhadra
Other articles of these authors
No other articles by these authors.
